Rallybio (RLYB) Fundamentals 2026 — Revenue Analysis | SniperIQ

6.64 on the NASDAQ. This SniperIQ fundamentals page covers Rallybio's valuation, profitability (net margin -911.1%), revenue ($858,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Rallybio's market cap?

Rallybio (RLYB) has a market capitalization of approximately $88M, trading at

6.64 on the NASDAQ. Market cap moves with the live share price.

What is Rallybio's P/E ratio?

Rallybio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Rallybio?

Rallybio runs a net profit margin of -911.1%, a gross margin of -1517.1%, and an operating margin of -3278.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Rallybio generate?

Rallybio reported revenue of $858,000 for fiscal year 2025, with net income of -$9M and earnings per share (EPS) of -1.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Rallybio pay a dividend?

Rallybio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Rallybio financially healthy?

Rallybio carries a debt-to-equity ratio of 0.00x and a current ratio of 12.92x, with a market beta of -0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Rallybio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rallybio (RLYB) the key facts are: market cap $88M, revenue $858,000, 52-week range 3.2-17.574. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.